Cancer has emerged as one of Nigeria’s most severe and rapidly escalating health crises, ranking as the third leading cause of mortality after cardiovascular and infectious diseases. The country records an estimated 280,000 to 350,000 new cancer cases annually, yet has fewer than 15 functional private radiotherapy machines serving a population exceeding 230 million people. This structural imbalance has created a treatment gap estimated at between 70 and 85 percent, meaning that the majority of cancer patients either receive no treatment at all or are forced to travel abroad to countries such as India, the United Kingdom, and Turkey at prohibitive personal cost.
Despite the severity of this public health burden, the Nigerian oncology market is estimated at between NGN 420 billion and NGN 680 billion annually. This places oncology among the largest and least competitively served healthcare markets in sub-Saharan Africa. Within this context, South Eastern Nigeria emerges as the most commercially and strategically attractive entry point for private investment in cancer treatment infrastructure due to its large population, strong diaspora-linked healthcare demand, expanding middle class, high incidence of medical travel abroad, and complete absence of private radiotherapy infrastructure.
This Investment Guide by Foraminifera Market Research Limited provides a comprehensive framework for the establishment of a Cancer Treatment and Radiotherapy Centre in South Eastern Nigeria. It examines the epidemiology of cancer in Nigeria, the regional demand structure, the proposed clinical service model, infrastructure and equipment requirements, regulatory frameworks, financial projections, and implementation pathways required for institutional-level investment decision-making.
The Nigerian cancer landscape is defined by three interrelated structural crises. The first is a steadily rising incidence of cancer, increasing at an estimated annual rate of four to six percent due to population growth, urbanisation, and changing lifestyle and environmental risk factors. The second is the late-stage diagnosis problem, where most patients present at advanced stages of disease due to the absence of systematic screening programmes and weak public awareness systems. The third is the severe treatment access deficit, where even diagnosed patients are unable to access consistent radiation therapy, chemotherapy, or specialist surgical oncology services.
Nationally, cancer incidence is estimated at between 280,000 and 350,000 new cases annually, with deaths ranging between 180,000 and 240,000 per year. This results in a five-year survival rate of approximately 15 to 28 percent, compared to 55 to 75 percent in countries with functional oncology systems. This survival gap is driven primarily by treatment inaccessibility rather than biological differences in disease characteristics.
South Eastern Nigeria accounts for approximately nine to eleven percent of this burden, translating to an estimated 25,000 to 38,000 new cancer cases annually and between 16,000 and 26,000 deaths. The most prevalent cancers in the region include breast cancer, cervical cancer, and prostate cancer, followed by colorectal cancers, lymphomas, and liver cancers. Cervical cancer presents a particularly severe treatment challenge because radiotherapy is a core component of its management, yet radiotherapy infrastructure is virtually nonexistent in the region.
The investment case for a Cancer Treatment and Radiotherapy Centre in South Eastern Nigeria is anchored on four structural realities. The first is the existence of large-scale unmet demand, with tens of thousands of patients requiring oncology services annually in a region with no private radiotherapy capacity. The second is the complete absence of competitive private specialist infrastructure, with Lagos serving as the nearest alternative, creating significant geographic and financial barriers to care. The third is the high level of medical expenditure leakage, as patients who can afford treatment currently spend between USD 18,000 and 45,000 abroad for services that could be delivered domestically at significantly lower cost. The fourth is the availability of policy and financing incentives, including Pioneer Status tax relief, BOI healthcare financing, and eligibility for international development finance institution participation.
The proposed facility is designed as a fully integrated specialist oncology centre rather than a general hospital with an oncology department. It will provide radiation oncology services using linear accelerator technology, medical oncology through chemotherapy and systemic cancer treatment, diagnostic oncology including imaging and pathology services, cancer screening programmes, palliative care, and digital oncology services such as telemedicine and remote consultation support.
Enugu is identified as the optimal primary location due to its central positioning within the South East, its established medical ecosystem including teaching hospitals and universities, and its relatively balanced cost structure compared to more commercially dense alternatives such as Onitsha or Awka. The facility is designed to operate initially as a 40 to 60-bed centre with one to two linear accelerators, supported by chemotherapy infusion units, diagnostic imaging systems, and a full laboratory and pathology suite, with expansion capacity built into the design.
The total oncology market in South Eastern Nigeria is estimated at between NGN 95 billion and NGN 155 billion annually, representing the theoretical value of comprehensive cancer care if access constraints were removed. Radiotherapy demand alone is estimated at between 12,000 and 18,000 patients annually, reflecting the proportion of cancer patients requiring radiation as part of their treatment pathway. However, the current supply of radiotherapy services in the region is effectively zero in the private sector.
The investable segment of this demand, defined as patients with both financial capacity and willingness to access private care, is estimated at between 1,500 and 4,500 patients annually. At prevailing pricing structures, this translates into a radiotherapy revenue potential of approximately NGN 2.5 billion to NGN 5.5 billion annually once the centre reaches operational maturity.
The facility operates on a multi-stream oncology revenue model anchored by radiation therapy as the highest-value service line. Chemotherapy services provide recurring revenue through treatment cycles, while diagnostic services including imaging, pathology, and treatment planning contribute high-margin procedural income. Cancer screening programmes create early detection pipelines, while outpatient consultations and institutional reimbursements from HMOs and insurers provide additional stable income streams.
The financial model projects first-year revenue in the range of NGN 850 million to NGN 1.35 billion, increasing to between NGN 2.8 billion and NGN 4.5 billion by Year 3, and reaching NGN 4.5 billion to NGN 7.2 billion by Year 5. EBITDA margins are projected to stabilise between 28 and 38 percent once operational efficiency is achieved. Over a ten-year horizon, equity internal rate of return is estimated at between 22 and 32 percent, with a payback period of approximately five to seven years from initial investment.
Total capital expenditure for the project is estimated at between NGN 3.8 billion and NGN 6.5 billion, depending on equipment specification, land cost, and facility design standards. Major cost drivers include linear accelerator procurement, radiation shielding construction, diagnostic systems, land acquisition, and working capital requirements.
The recommended financing structure combines equity investment of approximately 45 to 55 percent, concessional debt from development finance or BOI at 25 to 35 percent, and equipment leasing arrangements for high-value medical systems accounting for the remaining portion. This blended structure reduces upfront capital burden while improving overall return on equity.
The most significant operational constraint is the shortage of qualified radiation oncologists and medical physicists in Nigeria. This is mitigated through diaspora recruitment strategies, visiting specialist programmes, and structured international partnerships. Regulatory risk, particularly related to licensing from the Nigerian Atomic Energy Commission, represents another major constraint due to extended approval timelines, requiring early engagement and integration into the project development schedule. Equipment importation delays also represent a known risk, typically managed through early procurement planning and specialised customs facilitation.
Beyond financial returns, the project has significant systemic healthcare impact. It is expected to create over one hundred direct specialist healthcare jobs, introduce new oncology disciplines into the South Eastern Nigerian medical ecosystem, and significantly reduce medical tourism expenditure abroad. Most importantly, it has the potential to improve survival outcomes for thousands of cancer patients annually by providing timely access to evidence-based radiation therapy and integrated oncology care within the region.
Over a ten-year period, the facility could contribute to between 4,000 and 15,000 additional cancer survivors compared to the current baseline, representing one of the most significant measurable health impacts achievable through private healthcare investment in the region.
The establishment of a Cancer Treatment and Radiotherapy Centre in South Eastern Nigeria represents a rare convergence of unmet clinical demand, structural market failure, strong financial viability, and meaningful social impact. The opportunity is supported by clear policy incentives, a large addressable patient population, and a growing ability of patients to pay for high-quality private healthcare services.
Although the investment requires significant capital, technical expertise, and regulatory navigation, the underlying fundamentals are strong and defensible. From both a commercial and societal perspective, the opportunity represents one of the most compelling healthcare infrastructure investments available in Nigeria today.
The investment recommendation is clear: this is a high-impact, high-need, and financially viable opportunity that warrants serious institutional consideration.
